Charles Schwab’s Hinge Health HNGE Stock Holding History

Charles Schwab’s Portfolio HNGE Stock Details HNGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24M	Buy	289,608 +199,950	+223%	+$10.9M	﹤0.01%	1721
2026 Q1	$3.46M	Buy	89,658 +1,474	+2%	+$61.3K	﹤0.01%	2554
2025 Q4	$4.1M	Sell	88,184 -2,101	-2%	-$101K	﹤0.01%	2538
2025 Q3	$4.43M	Buy	+90,285	New	+$4.72M	﹤0.01%	2496

Other funds holding HNGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

12CM

11.2 Capital Management Las Vegas, Nevada $205M AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Charles Schwab's HNGE Position: Q2 2026 in Review

Charles Schwab increased its Hinge Health (HNGE) stake by 223% in Q2 2026, buying an estimated $10.9M and bringing the position to 289,608 shares worth $24M. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

Charles Schwab first reported a position in HNGE in Q3 2025 and has held it in 4 quarters since. 276 funds tracked by Wall St. Rank hold HNGE as of Q2 2026.

Charles Schwab held 289,608 shares of Hinge Health worth $24M as of Q2 2026.
Charles Schwab bought 199,950 Hinge Health shares in Q2 2026, an estimated $10.9M.
Hinge Health made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1721 holding.
Charles Schwab first reported a position in Hinge Health in Q3 2025 and has held it in 4 quarters since.
276 funds tracked by Wall St. Rank held Hinge Health as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.